down arrow

Pliant Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7291391057
USD
1.31
-0.18 (-12.08%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.151.67

52 Week

1.1015.27
Valuation
Technical
Day's Volume

CASH

15.68 M

Shareholding (Mar 2025)

FII

22.57%

Held by 93 FIIs

DII

31.18%

Held by 45 DIIs

Promoter

10.80%

How big is Pliant Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Pliant Therapeutics, Inc. has a market capitalization of 80.42 million, with net sales of 0.00 million and a net profit of -219.51 million for the latest four quarters ending in March 2025. As of December 2024, the company reported shareholder's funds of 304.08 million and total assets of 396.95 million.

Market Cap: As of Jun 18, Pliant Therapeutics, Inc. has a market capitalization of 80.42 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, Pliant Therapeutics reported net sales of 0.00 million and a net profit of -219.51 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 304.08 million and total assets of 396.95 million.

Read More

What does Pliant Therapeutics, Inc. do?

22-Jun-2025

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for fibrosis. As of March 2025, it has a market cap of $80.42 million and reported a net profit loss of $56 million.

Overview:<BR>Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -56 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 80.42 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.07<BR>Return on Equity: -85.36%<BR>Price to Book: 0.31<BR><BR>Contact Details:<BR>Address: 260 Littlefield Avenue, Suite 150, SOUTH SAN FRANCISCO CA: 94080<BR>Tel: 1 650 4816770<BR>Website: https://pliantrx.com/

Read More

Who are in the management team of Pliant Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Pliant Therapeutics, Inc. includes Dr. Bernard Coulie (CEO), Dr. Hoyoung Huh (Lead Independent Director), Mr. David Pyott, Dr. Suzanne Bruhn, Ms. Gayle Crowell, and Dr. John Curnutte, all serving as directors. They guide the company's strategic direction and operations.

As of March 2022, the management team of Pliant Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Bernard Coulie, who serves as the President, Chief Executive Officer, and Director.<BR>- Dr. Hoyoung Huh, who is the Lead Independent Director.<BR>- Mr. David Pyott, who is a Director.<BR>- Dr. Suzanne Bruhn, who is an Independent Director.<BR>- Ms. Gayle Crowell, who is also an Independent Director.<BR>- Dr. John Curnutte, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the company in its strategic direction and operations.

Read More

Is Pliant Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 6, 2024, Pliant Therapeutics, Inc. is considered overvalued at $1.25, with unfavorable valuation metrics and a year-to-date return of -90.51%, indicating a significant deterioration in its financial standing compared to peers.

As of 6 May 2024, the valuation grade for Pliant Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its current price of $1.25, especially when compared to its peers. Key ratios include a Price to Book Value of 0.39 and an EV to EBITDA of 0.75, which suggest that the company's valuation metrics are not favorable compared to the industry.<BR><BR>In comparison to its peers, Pliant Therapeutics, Inc. has a negative P/E ratio of -0.3663, while Aurinia Pharmaceuticals, Inc. holds a fair valuation with a P/E of 18.6866. Additionally, Disc Medicine, Inc. is also classified as does not qualify but has a significantly worse EV to EBITDA ratio of -7.7346. The company's recent performance has been poor, with a year-to-date return of -90.51%, starkly contrasting with the S&P 500's return of 2.44% in the same period, further reinforcing the view that Pliant is overvalued.

Read More

Is Pliant Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Pliant Therapeutics, Inc. has shifted to a mildly bearish trend, with mixed indicators showing a significant year-to-date underperformance of -88.69% compared to the S&P 500's 12.22%.

As of 21 August 2025, the technical trend for Pliant Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish monthly, while Bollinger Bands show a similar pattern. The daily moving averages are bearish, and the Dow Theory indicates a mildly bearish trend on the weekly chart, contrasting with a mildly bullish stance on the monthly chart. <BR><BR>In terms of performance, Pliant Therapeutics has significantly underperformed against the S&P 500, with a year-to-date return of -88.69% compared to the S&P 500's 12.22%. This stark contrast highlights the ongoing challenges faced by the stock.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 106 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

-94.04%

stock-summary
Price to Book

0.48

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-43 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.39%
0%
-23.39%
6 Months
-18.13%
0%
-18.13%
1 Year
-91.05%
0%
-91.05%
2 Years
-90.74%
0%
-90.74%
3 Years
-92.65%
0%
-92.65%
4 Years
-89.32%
0%
-89.32%
5 Years
-95.36%
0%
-95.36%

Pliant Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Pliant Therapeutics, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Pliant Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish monthly, while Bollinger Bands show a similar pattern. The daily moving averages are bearish, and the Dow Theory indicates a mildly bearish trend on the weekly chart, contrasting with a mildly bullish stance on the monthly chart. In terms of performance, Pliant Therapeutics has significantly underperformed against the S&P 500, with a year-to-date return of -88.69% compared to the S&P 500's 12.22%. This stark contrast highlights the ongoing challenges faced by the stock....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-235.26%
EBIT to Interest (avg)
-105.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.39
EV to EBIT
0.74
EV to EBITDA
0.75
EV to Capital Employed
10.02
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1348.03%
ROE (Latest)
-85.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 40 Schemes (35.45%)

Foreign Institutions

Held by 93 Foreign Institutions (22.57%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 22.95% vs -13.08% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.10",
          "val2": "-58.50",
          "chgp": "22.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.30",
          "val2": "-56.20",
          "chgp": "22.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -83.51% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -30.38% vs -30.82% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.60",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-226.20",
          "val2": "-182.30",
          "chgp": "-24.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "1.30",
          "chgp": "130.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-210.30",
          "val2": "-161.30",
          "chgp": "-30.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-116,547.50%",
          "chgp": "11,654.75%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-45.10
-58.50
22.91%
Interest
0.80
0.80
Exceptional Items
0.00
0.00
Consolidate Net Profit
-43.30
-56.20
22.95%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 22.95% vs -13.08% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
1.60
-100.00%
Operating Profit (PBDIT) excl Other Income
-226.20
-182.30
-24.08%
Interest
3.00
1.30
130.77%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-210.30
-161.30
-30.38%
Operating Profit Margin (Excl OI)
0.00%
-116,547.50%
11,654.75%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -83.51% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -30.38% vs -30.82% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pliant Therapeutics, Inc. stock-summary
stock-summary
Pliant Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-ß). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avß1. The Company’s second clinical-stage product candidate, PLN-1474, is a small-molecule, selective inhibitor of avß1 in development for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Company Coordinates stock-summary
Company Details
260 Littlefield Avenue, Suite 150 , SOUTH SAN FRANCISCO CA : 94080
stock-summary
Tel: 1 650 48167701 650 4816770
stock-summary
https://pliantrx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."